• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS Co-CEO, Paul Vulto, nominated as new Netherlands Academy of Engineering Fellow

The Hague, November 2, 2023 – Netherlands Academy of Engineering nominates MIMETAS CEO, Paul Vulto as a new Fellow, alongside 61 others, to actively contribute to their mission. This nomination emphasizes the crucial role of innovative technological solutions in addressing pressing societal challenges and sustainable change.

The Netherlands Academy of Engineering (NAE) has appointed 62 top experts to accelerate technological innovation for societal change. Their focus will be on fostering an innovation ecosystem that generates societal and economic value by providing engineering-based solutions to major societal challenges while simultaneously creating new business opportunities and export potential.

NAE is a member of international academies, including the European Council of Academies of Applied Sciences, Technologies, and Engineering, enabling NAE to represent the Netherlands on an international level and translate foreign insights into the Dutch context. NAE’s mission is to foster the prudent utilization of technology to achieve innovations necessary for a sustainable society with widespread accessibility to quality healthcare, nutrition, energy, water, and housing.

Dr. Paul Vulto, CEO of MIMETAS, a leading company in the field of organ-on-a-chip technology, is among the distinguished professionals nominated as NAE fellows. Dr. Vulto is recognized for his international pioneering activities in the Organ-on-a-Chip space and his breakthrough microfluidic discoveries such as PhaseGuide™ technology and the OrganoPlate® platform. This nomination emphasizes the crucial role of innovative technological solutions in addressing pressing societal challenges and sustainable change. His work at MIMETAS has been instrumental in advancing the development of cutting-edge solutions for drug testing, disease modeling, and personalized medicine. With this prestigious nomination, he will actively contribute to NAE's mission, sharing his expertise in the realm of microfluidic and Organ-on-a-Chip technology and science-based entrepreneurship.

NAE fellows will share their knowledge and skills through the NAE forum, translate insights into practical advice, and work towards removing barriers and fostering tangible innovation initiatives. Starting in 2024, NAE will annually select ten new fellows.

Read the press release (Dutch) Sign up for our Newsletter

Cookies

‘May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy

Accept all
Accept selected
Decline all